Physiomics Plc(PYC)
GBX --+0.00%
Reward32Low
Risk53Moderate
📊75%Data
Thin -48% profit margin · Revenue growing 49% YoY
PYC
+0.0 · +0.00%
GBX · LSE
Physiomics Plc | Healthcare
Capital Destroyer
Market Cap:1.52M
ℹ️
Reward Rating
32
Low
Bottom 1% (model universe)
75% data coverage
ℹ️
Risk Rating
53
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on PYC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 0p.

What is Physiomics Plc?

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.

PYC · Verdict

Limited reward · elevated risk

PYC's standout is balance sheet; profitability and cash flow weigh on the picture.

Based on 88% data coverage

PYC · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet86/100

    Current ratio 4.38

Watchouts 3

  • Profitability9/100

    -53% net margin · -120% ROE

  • Cash flow9/100

    -70% free-cash-flow margin

  • Growth25/100

    Rev -1.9% CAGR · earnings +17.9%

Model-based scoring. For information only — not financial advice.

What is Physiomics Plc?

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 1.52M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (32)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.52M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.799
52 Week Low0.2525
Last AnnualJune
IPO DateN/A
IncorporatedUK
Shares Outstanding303M
No. of Employees10
IndustryBiotechnology
ExchangeLSE
Beta1.013
CurrencyGBX · Reports in GBP